Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
13 hedge funds and large institutions have $243K invested in Immune Pharmaceuticals Inc. in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
13% less funds holding
Funds holding: 15 → 13 (-2)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
50% less capital invested
Capital invested by funds: $483K → $243K (-$240K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37.4K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$4.13K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$421 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$25K |
| 2 |
LPL Financial
San Diego,
California
|
-$10.3K |
| 3 |
EEG
E.E. Geduld
|
-$5.13K |
| 4 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$4K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$2.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $92K | +$37.4K | +3,645 | +52% |
|
|
SCM
2
Sio Capital Management
New York
| $85K | – | – | – |
|
|
BFA
3
BlackRock Fund Advisors
San Francisco,
California
| $29K | -$2.6K | -253 | -7% |
|
|
EEG
4
E.E. Geduld
| $11K | -$5.13K | -500 | -29% |
|
|
5
LPL Financial
San Diego,
California
| $10K | -$10.3K | -1,000 | -50% |
|
|
VKH
6
Virtu KCG Holdings
New York
| $8K | +$4.13K | +402 | +77% |
|
|
IFS
7
Ifrah Financial Services
Little Rock,
Arkansas
| $6K | -$1.03K | -100 | -13% |
|
|
BIM
8
BlackRock Investment Management
Wilmington,
Delaware
| $1K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $1K | +$421 | +41 | +76% |
|
10
Geode Capital Management
Boston,
Massachusetts
| $42 | – | – | – |
|
|
PRCM
11
Pine River Capital Management
Minnetonka,
Minnesota
| – | -$4K | -12,500 | Closed |
|
|
12
Goldman Sachs
New York
| – | -$25K | -1,692 | Closed |
|
IMNP Hedge Fund Activity: Q1 2016 in Review
13 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q1 2016, worth a combined $243K — down 50% from $483K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IMNP and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $37.4K. The largest seller was Goldman Sachs, exiting entirely with an estimated $25K sold.
- 13 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q1 2016, down from 15 in Q4 2015.
- Funds reported $243K of Immune Pharmaceuticals Inc. stock for Q1 2016, down 50% quarter-over-quarter.
- 0 funds opened new Immune Pharmaceuticals Inc. positions in Q1 2016 and 2 closed out, a net change of -2 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q1 2016 was Vanguard Group, an estimated $37.4K added.
- The largest Immune Pharmaceuticals Inc. seller in Q1 2016 was Goldman Sachs, an estimated $25K sold.
Based on aggregated 13F filings for Q1 2016.